BR112015029318A2 - marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável - Google Patents

marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável

Info

Publication number
BR112015029318A2
BR112015029318A2 BR112015029318A BR112015029318A BR112015029318A2 BR 112015029318 A2 BR112015029318 A2 BR 112015029318A2 BR 112015029318 A BR112015029318 A BR 112015029318A BR 112015029318 A BR112015029318 A BR 112015029318A BR 112015029318 A2 BR112015029318 A2 BR 112015029318A2
Authority
BR
Brazil
Prior art keywords
bowel syndrome
irritable bowel
diagnosis
specific markers
pathway specific
Prior art date
Application number
BR112015029318A
Other languages
English (en)
Inventor
Selvaraj Fabiyola
Princen Fred
Singh Sharat
Westin Stefan
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112015029318A2 publication Critical patent/BR112015029318A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

resumo patente de invenção: "marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável". a presente invenção se refere a métodos para auxiliar no diagnóstico da síndrome do intestino irritável (ibs) em um indivíduo. em particular, a presente invenção é útil para determinar se o indivíduo não tem ou doença celíaca ou doença intestinal inflamatória (ibd), e tem síndrome do intestino irritável e/ou em um subtipo da mesma. deste modo, a presente invenção se refere a um prognóstico de diagnóstico preciso da síndrome do intestino irritável e é útil para orientar as decisões de tratamento.
BR112015029318A 2013-05-24 2014-05-22 marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável BR112015029318A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827506P 2013-05-24 2013-05-24
PCT/IB2014/061636 WO2014188378A1 (en) 2013-05-24 2014-05-22 Pathway specific markers for diagnosing irritable bowel syndrome

Publications (1)

Publication Number Publication Date
BR112015029318A2 true BR112015029318A2 (pt) 2017-07-25

Family

ID=50884973

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015029320A BR112015029320A8 (pt) 2013-05-24 2014-05-22 Ensaios específicos de vias para predição de diagnóstico de síndrome do intestino irritável
BR112015029318A BR112015029318A2 (pt) 2013-05-24 2014-05-22 marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112015029320A BR112015029320A8 (pt) 2013-05-24 2014-05-22 Ensaios específicos de vias para predição de diagnóstico de síndrome do intestino irritável

Country Status (14)

Country Link
US (5) US9891235B2 (pt)
EP (2) EP3004068A2 (pt)
JP (4) JP2016520199A (pt)
KR (2) KR20160010621A (pt)
CN (2) CN105392780A (pt)
AU (3) AU2014269960B2 (pt)
BR (2) BR112015029320A8 (pt)
CA (2) CA2912993A1 (pt)
HK (2) HK1223361A1 (pt)
IL (2) IL242597B (pt)
MX (1) MX367046B (pt)
RU (2) RU2015155590A (pt)
SG (2) SG11201509371XA (pt)
WO (2) WO2014188378A1 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392780A (zh) 2013-05-24 2016-03-09 雀巢产品技术援助有限公司 用于预测肠易激综合征诊断的途径特异性测定
AU2014284047B2 (en) 2013-06-21 2018-11-22 Ondek Pty Ltd Immunotherapy composition and use thereof
MA39963A (fr) * 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
ES2748692T3 (es) 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
AU2015348940A1 (en) 2014-11-19 2017-05-25 Société des Produits Nestlé S.A. Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
DK3221331T3 (da) 2014-11-19 2019-12-02 Nzp Uk Ltd 6-alkyl-7-hydroxy-4-en-3-on-steroider som mellemprodukter til fremstilling af steroide fxr-modulatorer
CN107108687B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
EP3221334B1 (en) 2014-11-19 2020-02-19 Nzp Uk Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
EP3227685A1 (en) * 2014-12-02 2017-10-11 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
CN105987995A (zh) * 2015-02-04 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgG类抗体的酶联免疫试剂盒
CN105987996A (zh) * 2015-02-09 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgA类抗体的酶联免疫试剂盒
CN105061305A (zh) * 2015-08-31 2015-11-18 河南师范大学 一步合成3-甲基-2-吡啶甲酸甲酯的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106399344B (zh) * 2016-06-01 2021-01-01 上海领潮生物新材料有限公司 一种vin-cdtb融合蛋白的制备方法
WO2018011691A1 (en) * 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
CN106188191A (zh) * 2016-07-13 2016-12-07 西安电子科技大学 基于gsh响应的诊治一体化有机分子探针及其制备方法
CN110249048A (zh) * 2016-09-15 2019-09-17 太阳基因组学公司 用于从样品中的一种或多种类型的微生物的多样性群体中提取核酸分子的通用方法
US10428370B2 (en) 2016-09-15 2019-10-01 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN110072519A (zh) 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
EP3554540B1 (en) 2016-12-14 2023-08-02 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
JP2020513280A (ja) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド 消化管疾病の免疫抑制剤による治療
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
EP3554344A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018112240A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20200253506A1 (en) 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183941A2 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
EP3750168A1 (en) * 2018-02-09 2020-12-16 Metabolomic Diagnostics Limited A system and method of generating a model to detect, or predict the risk of, an outcome
CN111886501A (zh) * 2018-03-19 2020-11-03 富士胶片和光纯药株式会社 精神疾病的判断方法
CN112020651A (zh) * 2018-04-24 2020-12-01 根特大学 用于家禽肠道健康的肠道和粪便生物标志物
WO2019232295A1 (en) 2018-06-01 2019-12-05 Progenity, Inc. Devices and systems for gastrointestinal microbiome detection and manipulation
AU2019281024A1 (en) 2018-06-07 2020-12-24 4D Pharma Plc Method for stratifying IBS patients
CN110607335B (zh) * 2018-06-14 2021-08-03 中国科学院微生物研究所 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法
CN109324132A (zh) * 2018-10-31 2019-02-12 杭州佰辰医学检验所有限公司 高通量检测色氨酸及其代谢产物的试剂盒及其应用
US11488699B1 (en) 2018-12-09 2022-11-01 Cerner Innovation, Inc. Microbiota activity sensor and decision support tool
US11842795B1 (en) * 2018-12-17 2023-12-12 Cerner Innovation, Inc. Irritable bowel syndrome diagnostic sensor and decision support tool
EP3947744A1 (en) * 2019-04-03 2022-02-09 4D Pharma Cork Limited Methods of diagnosing disease
JPWO2020213732A1 (ja) * 2019-04-18 2021-04-30 株式会社サイキンソー 過敏性腸症候群の検査方法
US11884958B2 (en) * 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
WO2020232262A1 (en) * 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
CN111351870A (zh) * 2019-12-03 2020-06-30 康美华大基因技术有限公司 一种肠易激综合征血清代谢标记物组合及其诊断试剂盒
EP4085256B1 (en) 2020-01-27 2024-01-24 Immundiagnostik AG Test and in vitro diagnosis of irritable bowel syndrome
WO2021152586A1 (en) * 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN114755313A (zh) * 2021-01-08 2022-07-15 复旦大学附属华山医院 包含尿液nad+代谢物的急性肾损伤标志物
CN115724779B (zh) * 2021-09-01 2024-03-29 四川大学 酰胺烷二硫化合物、其制备方法和用途
WO2023122320A1 (en) * 2021-12-24 2023-06-29 Kuleon Llc Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists
WO2023180899A1 (en) * 2022-03-21 2023-09-28 Swain Manish Kumar Device and method for detecting diarrhea
CN116381222A (zh) * 2023-03-23 2023-07-04 北京巴瑞医疗器械有限公司 一种血清素发光免疫检测方法及血清素检测试剂盒
CN116990498A (zh) * 2023-09-28 2023-11-03 山东大学齐鲁医院 血浆色氨酸代谢物在儿童偏头痛诊断中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6218129B1 (en) * 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
BR0016467A (pt) * 1999-12-15 2002-08-27 Cubist Pharm Inc Lipopeptìdeos como agentes antibacterianos
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
CA2549971A1 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20100094560A1 (en) 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8278057B2 (en) 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
EP2419529B1 (en) 2009-04-14 2015-05-20 Nestec S.A. Inflammatory bowel disease prognostics
US20120171672A1 (en) 2009-04-14 2012-07-05 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP2778685B1 (en) * 2009-06-25 2017-04-26 Nestec S.A. Methods for diagnosing irritable bowel syndrome
KR20120101038A (ko) * 2009-10-30 2012-09-12 프로메테우스 레버러터리스 인코포레이티드 과민성대장증후군을 진단하는 방법
BR112012012513A2 (pt) * 2009-11-25 2017-01-10 Prometheus Lab Inc método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
US8445215B1 (en) * 2010-07-23 2013-05-21 Nestec S.A. Assays and methods for the detection of Crohn's disease
EP2710383B1 (en) * 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
EP2769321B1 (en) 2011-10-21 2016-06-01 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
EP2904395B1 (en) * 2012-10-05 2018-09-05 Nestec S.A. Antibodies to microbiome as diagnostic markers for ibs
CN105392780A (zh) 2013-05-24 2016-03-09 雀巢产品技术援助有限公司 用于预测肠易激综合征诊断的途径特异性测定
SG11201604495PA (en) * 2013-12-04 2016-07-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules

Also Published As

Publication number Publication date
AU2014269961A1 (en) 2015-11-26
US9891235B2 (en) 2018-02-13
JP2016520199A (ja) 2016-07-11
WO2014188377A3 (en) 2015-03-05
BR112015029320A2 (pt) 2017-07-25
HK1223361A1 (zh) 2017-07-28
RU2015155552A (ru) 2017-06-27
SG11201509371XA (en) 2015-12-30
SG11201509370UA (en) 2015-12-30
JP2019194600A (ja) 2019-11-07
KR20160013163A (ko) 2016-02-03
JP2016521683A (ja) 2016-07-25
IL242597B (en) 2019-02-28
US20180321259A1 (en) 2018-11-08
WO2014188377A2 (en) 2014-11-27
JP2019151637A (ja) 2019-09-12
CN105579852A (zh) 2016-05-11
CN105579852B (zh) 2017-12-01
US20170307637A1 (en) 2017-10-26
HK1223416A1 (zh) 2017-07-28
CA2912993A1 (en) 2014-11-27
RU2015155590A (ru) 2017-06-29
BR112015029320A8 (pt) 2023-01-03
CA2913108A1 (en) 2014-11-27
EP3004892A1 (en) 2016-04-13
AU2018214104A1 (en) 2018-08-30
US10338083B2 (en) 2019-07-02
AU2014269960A1 (en) 2015-11-26
CN105392780A (zh) 2016-03-09
US10036759B2 (en) 2018-07-31
IL242595B (en) 2019-01-31
WO2014188378A1 (en) 2014-11-27
EP3004892B1 (en) 2018-10-10
US20160130279A1 (en) 2016-05-12
MX367046B (es) 2019-08-02
US20180136233A1 (en) 2018-05-17
US20160139148A1 (en) 2016-05-19
KR20160010621A (ko) 2016-01-27
AU2014269960B2 (en) 2018-05-10
EP3004068A2 (en) 2016-04-13
US9739786B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
CA2941917C (en) Methods for the diagnosis and treatment of inflammatory bowel disease
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2015015532A (es) Metodo y sistema de identificacion de biomarcadores.
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
MX2015015561A (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112014025189A2 (pt) prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
WO2015070001A3 (en) Compositions and methods for detecting and/or treating inflammation
MX2018001831A (es) Biomarcadores para el tratamiento de alopecia areata.
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
EP3045916A4 (en) Kit and method for diagnosis, prognosis or monitoring of liver disease through measurement of amount of ast
WO2014169011A3 (en) Methods for treating immune diseases

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]